Interleukin-18 (IL-18) is a pro-inflammatory cytokine that modulates innate and adaptive immune responses. Decoy-resistant IL-18, DR-18, from Simcha Therapeutics Inc., is an engineered IL-18 cytokine able to interact with the IL-18 receptor but resistant to IL-18-binding protein (IL18BP), which is a negative regulator of IL-18 signaling, thus overcoming the antitumoral efficacy limitation seen with recombinant IL-18.
Biper Therapeutics SAS has announced bridge financing of €800,000 (US$839,000), ahead of the closure of its series A funding round, to advance its pipeline of drug candidates overstressing pathological cells to treat diseases, including cancer.
Researchers from China Pharmaceutical University reported the discovery and preclinical characterization of allosteric inhibitors of Src homology-2-containing protein tyrosine phosphatase 2 (SHP2) as potential new anticancer agents.
Iregene Therapeutics (Suzhou) Co. Ltd. has identified pyrazolecarbonyl piperazinone compounds acting as bone morphogenetic protein receptor type-1B (BMPR1B) inhibitors reported to be useful for the treatment of cancer and pulmonary hypertension.
B7H3 is a pan-cancer antigen considered a promising target for immunotherapy. However, targeting B7H3 using bispecific T-cell engagers (BiTEs) presents the problem of systemic toxicity.
SK Biopharmaceuticals Co. Ltd. has signed a research collaboration agreement with Proen Therapeutics Inc. to further extend its oncology research capability and expand its pipeline of radiopharmaceutical therapies.
Cathepsin G (CTSG) is overexpressed and aberrantly localized for antigen presentation on acute myeloid leukemia blasts and stem cells compared to normal hematopoietic progenitors. Earlier this year, Crossbow Therapeutics Inc. announced the nomination of its first development candidate, CBX-250, a TCR-mimetic (TCRm) bispecific T-cell engager (TCE) antibody targeting a CTSG peptide-human leukocyte antigen (pHLA) complex and CD3.
The lack of acute myeloid leukemia-specific antigens is one of the challenges for targeted immunotherapy together with on-target off-tumor toxicities due to the expression of the target in normal myeloid cells. A subset of T cells – Vδ2 T-cells – which represent ~5% of the T-cell population in healthy donors, are seen as part of emerging immunotherapeutic strategies.
RSS
